More on Illumina (ILMN): The stock is trading higher in the post session as its Q1 easily beats across the board on a 21% jump in revenue Y/Y. The company swung to a net loss for the quarter however, after taking nearly a $107M loss related to its unfavorable verdict in its patent litigation with Syntrix Biosystems. R&D and SG&A expenses were both higher as a percentage of revenue, while margins were relatively flat compared to the prior year. Shares +4.3% AH.
More on Illumina (ILMN): The stock is trading higher in the post session as its Q1 easily beats...
From other sites
Video at CNBC.com (Jun 28, 2016)
Video at CNBC.com (Apr 19, 2016)
Video at CNBC.com (Oct 6, 2015)
at CNBC.com (Jan 9, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs